BMJ Neurology Open

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease

By Alok Kumar Dwivedi, Bruno Pietro Imbimbo, Jesus Thomas Abanto, Alberto J. Espay

Computational studyInterventions

The paper

Alok Kumar Dwivedi, Bruno Pietro Imbimbo, Jesus Thomas Abanto, Alberto J. Espay

University of Missouri; University of Cincinnati

BMJ Neurology Open, 10 Aug 2026

doi.org/10.1136/bmjno-2026-001649 PubMed 42602524

medRxiv4 Oct 2026
Remote digital test flags cognitive impairment in older adults
medRxiv5 Oct 2026
Blood eMTBR-tau linked to Alzheimer’s tangles at autopsy
Neurology4 Oct 2026
Plasma p-tau217 yields discordant Alzheimer results in 8.5% of adults
medRxiv4 Oct 2026
Tool converts plasma pTau217 values across testing platforms